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INTRODUCTION 
 
DEEP  VEIN  THROMBOSIS  is  a  clinical  challenge  for  
doctors  of   all  disciplines. It  can  complicate  the  course  of  a  disease  
but  might  be  encountered   the  absence  of  precipitating  disorders. 
Thrombosis  can  take  place  in  any section  of  the  venous  system ,  
but  arises  most  frequently  in  deep  veins  of   leg.  Long  term  
morbidity  due  to  post thrombotic  syndrome  was  common   and  may  
be  substantial.  The  major  concern,  however,  embolization  of  
thrombus  to  the  lung  which  can  be  fatal.  Deep  vein  thrombosis  is  
highly  prevalent  and  poses  a  burden  on  health economy. The  
disorders  and  its  sequalae   were  also  among  the  best  examples  of  
the  preventable  diseases . Relevant data  for  the  frequency  for  the  
deep  vein  thrombosis  derive  from  large  community  based   studies  
because  they mainly  reflect  the  symptomatic  rather  than  the  
asymptomatic   disease.   Two- thirds  of  the  first  deep  vein thrombosis   
are  caused  by  the  risk  factors  including  surgery ,  cancer ,  
immobilization , or  for  other  reasons. Risks for  first  deep  vein  
thrombosis  seem  to  be  higher   in  men  than  in  women. 
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RISK FACTORS FAVOURING DVT 
 Age 
 Obesity 
 Smoking 
 Cancer patients 
 Previous history of deep vein  thrombosis 
 Family history of thrombosis  
 Previous history of varicose vein 
 Chronic medical illness 
 History of connective tissue disorder 
 Chemo/ radiotheraphy received patients 
 Spinal/ general anaesthesia 
 Duration of surgery 
 Immobilization days 
Rudolph  virchow  is  recognized  as  the  first  person  to  link  the  
development  of  VTE  to  the  presence  of  atleast 1of 3  conditions: 
Venous stasis , vascular injury  and  hypercoagulability.  Some  of  
risk factors  can  alter  the  delicate  hemostatic balance  toward  the  
hypercoagulability  and  development  of  the  thrombosis. Coleridge-
smith et al12  reported  in  1990 that  venous  stasis  occur  during  
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general  surgery ,  with  veins  dilating  22 to 28 %  patients  undergoing   
general anaesthesia  and  surgery  and  upto   57 %  in  those  received   in  
infusion  of  1 litre  of  saline  during  the  surgery.  The investigators  
suggested  that  it  was  intraoperative  venous  distension  that  underlies  
the  risk  for  deep  vein  thrombosis in  patients  undergoing  surgery. 
They  suggested  that  the  venous  distension  was  the  result  of  loss  of   
muscle tone that  was  caused  by  the  muscle  relaxants  used  during  
the  surgery.  Muscle  paralysis  resulting  from  regional anaesthesia  
also  can  lead  to  venous  dilatation.  These  effects  can  be  modified  
to  some  extent  by the  use of graduated  compression stockings  during   
surgery.  The  venous  dilatation  that  occurs  during  surgery  causes  
cracks  in the  endothelium ,  which   provides  a nidus  for  the  
thrombosis  as  the  blood  coagulation  system  is activated. Microscopic 
vessel damage during surgery precipitating factor for DVT. The third 
factor in   virchow’s   triad , hypercoagulability  was  linked  to  the  
number  of  factors , including certain genetic traits.  Deficiencies of 
antithrombin , protein C , protein S  OR MUTATIONS OF FACTOR V  
LEIDEN , or factor  II ( prothrombin )  G 20210A   genes   lead  to  the  
hypercoagulable  states. 
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AIM AND OBJECTIVE OF THE STUDY 
 
 It  is  important  to  have  pre  operative  discussion  with  patients  
and  their  families  regarding  relative  risks  and benefits if particular 
thromboprophylaxis strategy. This could include realistic evaluation of 
the risk of serious DVT complications.  Individual  assessment  of  
thrombosis risk must be done in every patient to minimize morbidity and 
mortality of  DEEP  VEIN  THROMBOSIS  post  operatively.  And  also  
moderate  and  high  risk  group  patients definitely  need  the  
thromboprophylaxis  preoperatively  in order to  prevent  the  post  
operative  DVT.  
This  study  shows  various  risk  factors  related  to  DEEP  VEIN  
THROMBOSIS  and  prophylactic  management of   DEEP  VEIN  
THROMBOSIS. 
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REVIEW OF LITRATURE 
AGE 
Patients  >40  years  of  age  are   increased  risk  of  venous  
thromboembolism  compared  with  young  patients. With  the  risk  
approximately  doubling  with  each  decade  thereafter.  Further  
evidence  for  the  importance  of  age  as risk factor for deep vein 
thrombosis  was reported by oger in a study of the incidence of DVT in 
French communititon population. This  study  found  that  the  incidence  
of   DVT   risk  increasing  with   age ,  reaching >1%   inpatients  >75 
years  of  age. This study reported that the incidence of PE as a 
percentage of total VTE also increased with age. A subanalysis  of  data  
from  the  prophylaxis  of  DVT  in  medical  patients  with  ENOXaparin 
(medenox)  study  confirmed that  age  >75 years  is  an  independent  
risk  factor  for  VTE   in  patients  hospitalized  with  an  acute  and  
chronic medical  illness. Hence  old  age  patients  undergoing   surgery  
greater   risk  of   DVT   than  young  age  patients. 
OBESITY 
Investigations  that  reported  increased  risk  of   DVT  caused  by  
obesity   are   criticized   because  they  failed to include  the  duration  of  
hospital  confinement  or  other  risk  factor.  High  proportion  of  the  
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patients  with  DVT  has been  found  to  be  obese  but  the  importance  
of   the  association  was  diminished  because  of  the  high  proportion of  
obesity  in  the  general  population. The  Nurses’  health  study  showed  
that  the  age  related  risk  ratio  for  PE  women with the body mass 
index 29 kg/ m2  higher  was  3.2  times  compared  the  leanest  category  
of   less  than  21 kg/ m2.  The Framingham  heart  study  showed  that  
metropolitan  relative  weight  was  significantly  and  independently  
associated with  PE  among  women  not men.  However,  the  study  of  
men  born  in  1913  showed  that  men  in  the  highest decile of  waist  
circumference  >100cm  had  adjusted relative risk  of  DVT  3.92  times  
compared  with  men  with  Waist circumference of <100cm. Various 
abnormalities of haemostasis have been described in obesity , in 
particular increased plasminogen  activator inhibitor-1.  Other  
abnormalities  reported  include  1) platelet activation  2) increased 
plasmafibrinogen factor  and  von  willebrand  factor , Fibrinogen ,  
factor 7C  and  PAI-1. 
SMOKING 
The  patients  with  smokers  had  higher  risk  of  DVT  than  non 
smokers.  The  potential  influence  on  coagulation  offers further 
potential to contributed  to thrombogenesis in all smokers. Plasma 
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fibrinogen levels elevated in all smokers. Factor XIII , which  stabilized  
fibrin   Clots , is  increased  in  smokers. Exposure to  nicotine  may  also 
increase the plasminogen  activator inhibitor -1 ( a major regulator of 
fibrinolysis) , although extend to which nicotin enhances coagulation  is  
unresolved. Hence  the  deep  vein  thrombosis  is  potential  and  fatal  
complication  of  smoking. 
VARICOSE VEIN 
The  importance  of  varicose  veins are  independent  risk  factor  
for  DVT  is  currently   unclear.  Varicose  veins were identified  as  an  
independent  risk factor by heit et al  with  associated risk for venous 
thrombo embolism decreasing with age.  On  the  basis  of  the  sub  
analysis  of  data  from MEDENOX study ,  alikhan et al   have  reported 
VTE rate 21.3 percentage.  However ,  it must  be  noted  that  these  
patients  also  exhibited  numerous  other  risk  factors  of  venous 
thromboembolism. 
CONGENITAL HYPERCOAGULABLE DISORDERS 
Antithrombin  is  serine  protese  inhibitor  of  thrombin  and   also  
inhibits  factors  IXa ,Xa ,XIa  and XIIa. Thrombin  is  irreversibly  
bound  by  antithrombin  and  prevents  thrombin’s  action  on  fibrinogen   
on  factors   V ,VIII , XIII  and  on  platelets. The  anticoagulant  
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synthesized  in  liver  and  endothelial cells  and  has  a  half   life   of  2.8 
days. Anti thrombin deficiency  has  a  prevalence  of  1:5000  with  more  
than  100  genetic  mutations  and  an  autosomal inheritance pattern. 
Antithrombin deficiency  associated  with  lower  extremity  thrombosis  
as  well  as  mesenteric  venous thrombosis. The  most  common  
presentation  is   those   with    anti thrombin  deficiencies   are   deep  
vein  thrombosis with  or  without  pulmonary  embolism. 
PROTEIN C AND PROTEIN S DEFICIENCY 
Protein C  is  a vitamin  K  dependent  anticoagulant  protein  that , 
once  activated  by  thrombin , will  inactivate factor Va and VIIIa  
thereby  inhibiting  generation  of  thrombin. Additionally  activated  
protein C  stimulates the  release of  t-PA.  It  is  produced  in   the  liver  
and  is  the  dominant  endogenous  anticoagulant  with  eighty  hour  half 
life. Protein C deficiency  has  a  prevalence  of  1in 200 – 300  with  
more  than  150  mutations  and  an  autosomal  dominant inheritance. 
 Protein S  is  also  vitamin k  dependent  anticoagulant  protein  
that  is  cofactor  to  activated  protein C.  The actions  of  protein S  are  
regulated  by   complement  C4b   finding  protein  and   only   the   free  
form  of  protein S  serves  as  an  activated  protein C  cofactor.  
Additionally ,  protein S  appears  to  have  independent  anti coagulant 
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function  by  directly  inhibiting  procoagulant  enzyme  complexes.  The  
prevalence  of  protein S  deficiency  is  about 1  in 500  with  autosomal  
dominant  inheritance. 
FACTOR V  LEIDEN MUTATION AND ACTIVATED PROTEIN 
C RESISTANCE 
Factor  V  is  the  glycoprotein  synthesized  in  liver  with  factor 
V  leiden ,  a  point  mutation  occurs  when  arginine is  substituted  by  
glutamine  at  position 506.  The  activated  protein C  thus  causing  the  
procoagulant  state.  Clinically, patients  may  present   with  deep  vein  
thrombosis  in  lower  extremities , or  less  commonly  in  portal vein , 
cerebral veins  or  superficial  venous  system. 
PROTHROMBIN G20210 POLYMORPHISM 
Prothrombin (factor II)  is  a  zymogen  synthesized  in  liver  and  
dependent  on  vitamin K.  When  prothrombin  is activated , it  forms  
thrombin (factor IIa).  A  single  mutation  where  adenine  is  substituted   
for  guanine  occurs  at 20210 position . The  mechanism  for  increased  
thrombotic  risk  is  not  well  understood , but  this  individual  with  this 
genetic  variant  have  the  supranormal  level  of  prothrombin. The  
mutation  is  inherited  as  an  autosomal  dominant trait  and  is  
associated  with  both  arterial  and  venous  thrombosis. 
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Clinically , patients may  present  with  deep  vein  thrombosis  of  
lower  extremity ,  cerebral  venous  thrombosis, as well  as  arterial  
thrombosis.  The  risk  of   thrombosis  increased  in  the  presence  of  
other  genetic  coagulation  defects  and  with  acquired   risk  factors. 
OTHER COAGULATION FACTORS 
Elevated  levels  of  several  coagulation  factors ,  including  
factors  VIII , IX  and  XI , has  been  linked with increased  thrombotic  
risk.  In  the   leiden  thromophilia  study , 25% of  the  patients  with   
first  episode  of   DVT  had factor VIII levels >150% of normal 
compared with only 11% of healthy controls.  Plasma level of > 150 
IU/dL  was associated  with  almost  5 times  the risk  for  an  initial 
event.  These  findings  have  been  confirmed  in  the  several  other 
small  studies.  Furthermore , patients  with  prior  DVT   and   elevated  
factor  VIII   levels  are  at  significantly  increased risk  of    recurrent 
VTE. 
Elevations  in  plasma  levels  of  factors  IX  and  XI  also  appear  
to  modestly  increased  thrombotic risk. After excluding  subjects  with  
other  thrombophilic  disorders, patients  with  factors IX and XI levels  
were  above the 90th percentile in the leiden thrombophilia study  had  a  
2.5 fold and 2.2  fold   adjusted   risk  respectively ,  for venous 
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thrombosis  compared  with  those  with  lower  values.  As   with  actor 
VIII , the molecular   basis  for  an  elevated  factor IX  and  XI  level  
was   unknown , although  the  genetic  component  seems  likely. 
Further  information  was  needed  to  define  the  impact  of  these  
conditions  on  future  management  of  VTE , including  duration  of  
theraphy ,  prophylaxis  in  high  risk  clinical  situations , and  family  
screening   accordingly , the utility  of  screening  for  elevations  in  
these  factor  levels  in  patients  with   idiopathic  venous  thrombosis  
remains unclear. 
HYPERHOMOCYSTEINEMIA 
Homocysteine  is  an  aminoacid  formed  during  the  metabolism  
of   methionine  and  may  be  elevated  secondary to  Inherited   defects 
in  two enzymes  that   are  part  of  the  conversion  of  homocysteine  to  
cysteine .  The  two  enzymes involved  are  N5 ,  N10-methelene   tetra   
hydro   folatereductase or cystathione beta synthase.   
Hyperhomocysteinemia  had  been  shown  to  increased  the risk of 
atherosclerosis , atherothrombosis and venous thrombosis. Elevated 
plasma homocysteine levels were leads to various  dysfunction of  
endothelial cells leading to theprothrombotic   state. 
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Hypercoagulable syndromes include inherited and acquired 
thrombophilia. Acquired thrombophilia include antiphospholipid 
syndrome, heparin  induced thrombocytopenia ,  acquired  
dysfibrinogenemia ,  myeloproliferative disorder   and  malignancy.  
Regarding  the  anti-phospholipid  syndrome  antiphospholipid  
antibodies  were  associated with both arterial and venous thrombosis.  
The  most  commonly  detected  subgroup of   anti-phospholipid  
antibodies  were lupus anticoagulant  antibodies ,  anti cardiolipin  
antibodies , anti b2 glycoprotein I antibodies.  DVT  the  most common  
manifestation  of  antiphospholipid  syndrome , occurs  in  29 to  55 
percent  of  patients  with  this  syndrome , and  about  half  of  these  
patients  had   pulmonary  embolism. 
COPD 
COPD  patients  are  thought  at  increased  risk  of DEEP VEIN 
THROMBOSIS because of immobilization ,  heightened  inflammation , 
cigarette smoking , and  venous  stasis. DVT  however , remains  under   
diagnosed   because  its symptoms  mimics  a  COPD  exacerbation . 
overall  the  reported  prevalence  of  deep  vein  thrombosis  during  the  
COPD  patients  undergoing  surgery  ranges  from  5 to 29 % . Hence  
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COPD  patients  with  smoking  history  more  prone to   develop  deep  
vein  thrombosis  post operatively. 
CANCER 
CANCER RELATED FACTORS 
The frequency  of  DVT  increases  2 to 3 fold  in  patients  
undergoing  surgery  for  malignant  disease  compared with  those  
undergoing surgery  for the  nonmalignant  conditions.  Because  
malignancy  commonly  associated  with  other  riskfactors , the  direct  
effect  of  malignancy  on risk  is  uncertain.  Advanced  cancers  are  
associated  with  high  incidence of  DVT ,  especially  cancers  of  the  
breast ,  lung , brain , pelvis , rectum , pancreas  and gastrointestinal tract. 
Administration  of  chemotheraphy  increases  the risk.  For  example , 
patients  newly  diagnosed  with  multiple  myeloma receiving  
thalidomide  with  multiagent  chemotheraph  in  association  with  
surgery  have  3 times  risk  of  DVT  compared  with  women  undergo  
surgery  alone.   
SITE OF CANCER 
In studies looking at pooled groups of patients with different types 
of malignancy , the rate of venous thromboembolism  is  consistently  
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higher  with  cancer  of   the  stomach , pancreas , brain , kidney , uterus , 
lung or ovary. 
Both  large  retrospective  studies   by  stein et al   and  chew  et al  
based  on  discharge  claims  databases  reported the  highest  rates of 
DEEP VEIN THROMBOSIS  in patients  with  pancreatic cancer.  
Patients  with  stomach cancer had second  and  third   highest  risk  of  
developing  DVT in these studies .  In  patients  with   testicular  and  
lung  cancer   those with metastasis  to liver and  brain  were  shown to 
have higher rates of  DVT  compared with patients with other  sites of 
metastasis. 
CANCER  STAGE 
Multiple  studies  have  shown   an  increased  risk  of  DVT   in  
patients   with  advanced  stage  cancer.  In a population  based  case  
control  study  of  patients  with  newly  diagnosed  DVT  including  389  
patients  with  cancer those  with   distant  metastases  had  a  higher  risk  
of    DVT.  Other  studies  in  ovarian , colorectal , pancreatic , lung  and  
breast cancer  support  the  finding  that  advanced – stage  disease  
increases the  risk  of  cancer  associated  DVT. 
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HISTOLOGY 
In  certain  types  of  cancer , higher rates  of  DVT  are  found  in  
some  histological  subtypes  compared  with  others. In  breast   and   
colon  cancer patients , the  type   of  histology  does  not  predict  for  the  
incidence  of  cancer  associated   DVT ,  but  DVT   associated   
mortality  rates  are  higher  in patients  with  certain  histological  
subtypes. 
CHEMOTHERAPHY/RADIOTHERAPHY 
Chemotheraphy/radiotheraphy  is  one  of  the  most  important  
factors  in  DVT   risk  stratification  of  cancer  patients. Large  
population- based studies in groups  of  pooled  cancer patients have 
demonstrated  a significantly increased risk  in patients receiving 
chemotheraphy. Heit et al  used a population – based  study  of  patients  
with  a   new  diagnosis  of  DVT,  23 %  of   which  had  diagnosis  of  
active  malignancy ,  to  demonstrate  the significantly  increased  risk  of  
DVT  in  those  an  chemotheraphy/radiotheraphy. 
Studies  in  specific  type  of  cancer  and  with  specific  anti  
neoplastic  agents  have  also   supported  the  role  of  chemotheraphy  in  
predicting  the risk  of  cancer-associated  DVT. Two  prospective  
studies  of   breast  cancer  patients  demonstrated  that  the  risk  of  DVT  
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in  patients  receiving chemotheraphy  in  addition  to  tamoxifen  or  
surgery  or  radiotheraphy  increased  two  to  seven -fold. A  recent  meta  
analysis  of  breast  cancer patients  revealed  that  use  of  adjuvant  
hormonal  theraphy  was  associated  with   1.5 – 7   fold  increased  risk  
of   DEEP  VEIN  THROMBOSIS. 
CHRONIC MEDICAL ILLNESSES 
LIVER DISEASE 
Patients  with  chronic  liver  disease  (both with alcoholic and non 
alchoholic)  seems  to  have  higher  risk  of  DVT  than   patients  
without  liver disease . Chronic  liver  disease  may  result  in  impaired  
production  of  vitamin-k  dependent  procoagulant factors.  However  
decreased  production  of  vitamin –k   dependent  endogenous  
anticoagulants  such  as   protein C , protein S   and  antithrombin III   
may  counter  the  hypocoagulability  in   such patients. 
HYPOTHYROIDISM 
In view of  study  among  the  hospitalized  patients  with  a  
diagnosis  of  hypothyroidism   DVT  was  diagnosed   in  1.36 %  of  
hypothyroid patients. 
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MYOCARDIAL INFARCTION 
Myocardial  infarction  patients  are  associated  with  deep  vein  
thrombosis. The  deep  vein  thrombosis  risk  of  patients  hospitalized  
with  acute MI  are  comparable  with  that  of   moderate  risk  general  
surgical  patient  (20% overall and  2% symptomatic ) . The  number  of  
risk  factors  are commonly  associated   with  MI   including   age , bed 
rest , venous stasis  because  of  congestive  heart  failure   such  that  MI  
itself  has  not  been  clearly establized  as  an   independent  risk  factor  
for  DVT. 
CONNECTIVE TISSUE DISORDERS 
Systemic  inflammation  may  be  involved  in  the  pathogenesis  
of  deep  vein  thrombosis   through  the  vessel  wall  damage ,  
upregulations  of procoagulants ,  downregulation  of  anticoagulants , 
and  suppression  of  fibrinolysis.  Autoimmune diseases ,  which  are  
characterized  by  an  overactive immune  response  against  the  body’s  
own  tissue ,  may  therefore  increased  the  risk  for  deep  vein  
thrombosis. 
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SURGERY  
Surgery  is  a  well  known  risk  factor  for  development  of   
DVT  in  patients  without  cancer.  The  incidence  of  DVT  in  cancer  
patients undergoing  general  surgery  is  estimated  at 37%  compared  
with  20%  in  patients  without  cancer.  Factors   related  to  immobility ,  
tissue  destruction and  venous  stasis  were  likely  to  be  related  to  the  
increased  risk  of   DVT   after  surgery.  The  risk  of   DVT  after  
major  general   surgery  has  been extensively  documented.  Although  
the  term  major  general  surgery  is  imprecise ,  most  investigators  
apply  this  term  to  patients  who  are  undergo abdominal  or  thoracic  
operations  that  require  general  anaesthesia > 30 minutes.  
The recent  dramatic  increase  in  endoscopic  alternative  to  open  
surgery  has  not  been  accompanied  by  the  controlled  studies  of   
DVT   risk  although  adverse changes  in  haemostasis  after  
laparoscopy   have  been  reported.  Bergqvist  and  loweconcluded  in  
recent  review , that  laparoscopic cholecystectomy  is  low  risk  
procedure  such  that  routine  DVT  prophylaxis  is  probably  not  
justified.  But  the  decision  regarding  prophylaxis  for laparoscopy  
should  likely  be  made  in  the  same  manner  as  for  conventional  
surgery , customized  for  the  particular  risk   of  each  patient , taking 
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into  account  the  length  of  the  operation ,  amount  of  time  bed bound 
,  and comorbid conditions. 
IMMOBILIZATION 
Gibbs  found  that  15%  of  patients  on  bed rest  for  <1 week   
before  death   had  venous  thrombosis  at  autopsy ,  whereas  incidence  
rose  to 80%  in  patients  in  bed  for  a  longer  period.  The   influence  
of  immobility  as   risk  factor  was  particularly  striking  in  studies  of  
hemiplegia.  On the basis of fibrinogen scanning, warlow et al found 
asymptomatic DVT  in 60%  of  paralysed  limbs  of  stroke  patients  
compared  with  7 %  in  the nonparalyzed  limbs.  Whereas  prolonged  
bed rest  or immobilization  alone  not provide  adequate  reason  for  
prescribing  prophylactic  anticoagulant theraphy.  Prolonged  immobility  
combined  with  other  major  risk  factors  increases  the likelihood  of   
DEEP  VEIN  THROMBOSIS. 
There  has  been  recent  attention  in  the  popular  press  about  
the  risks  of   DVT  associated  with   long  duration   air travel   the so 
called economy class syndrome.  In a study of 231 subjects  without  
prior  history  of  DVT   who  were  embarking  in  flights    for    > 8 
hours   in duration , those  randomized  to  compression  stockings  had  
no  evidence  of   DVT  on  subsequent  duplex  ultra  sonography.  
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Conversely , 105 of untreated   individuals  developed  asymptomatic 
DVT.  Despite  these findings , there  is  general  consensus  that  
clinically  important  DVT   after  air  travel is  rare , and  that  benefits of  
providing DVT  prophylaxis  during  long  distance flights are  doubtful.  
Case   reports  suggest  that  most cases of  travel- related thrombosis  
affected people at risk because   previous DVT or  other predisposing 
factors.  Thus , until   the formal  study  validates  another approach , it 
makes  sense  to  provide   advice  to  such  people  regarding  hazards  
and  simple  precautions ,  including  frequent  leg  movement  and 
adequate hydration  during  long  flights.  
PROPHYLACTIC MEASURES OF DVT 
MECHANICAL METHODS 
ANTI EMBOLISM STOCKINGS 
Anti embolism  stockings exert  graded  circumferential pressure  
from distal to  proximal  region of  leg confirming to sigel pressure 
profile.  These increase  blood  velocity , promote venous return  ,and  
have been shown to be effective.   Anti-embolism stockings  should not 
be used if the patient had  peripheral  vascular disease , arteriosclerosis , 
severe peripheral neuropathy , massive  leg edema  or  pulmonary edema 
, oedema secondary to congestive heart  failure or local skin / soft tissue 
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diseases ,  and  in  patients  with  acute  stroke.  Thigh  length  stockings  
may  be  considered  preferable  as more effective  and  current  
evidences  are  poor.   However ,  If  these  are  not  suitable  because  of  
compliance  or fit ,  knee  length  versions  must   be  used.  
INTERMITTENT PNEUMATIC COMPRESSION 
Intermittent  pneumatic  compression  periodically  compresses  
the  calf  or   thigh  muscles  with  inflation  pressure  of   35 to 40 mm 
Hg   at  a  rate of   about  10 beats  per  minute.  They  mimic  muscle  
pump  with  effect  of   walking  ,  promote fibrinolysis  ,  and  have  been  
shown  to  reduce  DVT risk. 
FOOT IMPULSE DEVICES 
Foot impulse devices  (foot pumps)  increase  venous  outflow  and  
reduce  venous  stasis  in  immobilized  patients. They  are  designed  to  
mimic normal  walking  by  compressing  plantar  venous  plexus  
producing  the  pulsatile  flow  in the veins.  These  have  been  shown  to  
be  effective  after major  surgeries  in  reducing  the   asymptomatic  
DEEP  VEIN  THROMBOSIS. 
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PHARMACOLOGICAL METHODS 
Pharmacological prevention involves the perioperative 
administration of anti-coagulant drugs.  The agents  relevant  to currently 
practiced  were unfractionated  heparin , low molecular weight heparin , 
oral direct factor Xa inhibitor ,warfarin , aspirin , danaparoid , 
fondaparinux ,lepirudins  and dextrans. 
UNFRACTIONATED HEPARIN 
Heparin  is  naturally  occurring  anticoagulant  derived  mainly  
from  porcine  intestine  or  bovine  lung.  It  is  a   large   polysaccharide  
varying  size from  5 to 40  Kda.  It  finds to  endogenous  antithrombin ,  
producing  complex  that  inhibit  activated  coagulation  factors ,  
including  factor  Xa  and  IIa (thrombin).   Unfractionated  heparin  is  
effective  in  prevention of  DVT.  However , subcutaneous  
administration  was  less  predictable  than  LMW heparin , it does  have  
an   easily measurable  mode  of  action ,  was  reversible ,  and  may  be  
preferred  in  patients  with  renal  failure.  For  most patients  it  is  
inconvenient  to  deliver , may  induce  greater  bleeding  risk  when  
compared  with  LMWH , and  may  cause  the  rare  complication  of 
heparin  induced  thrombocytopenia. Unfractionated  heparin  is  
delivered  as  twice or  three  times  per  day  subcutaneous  injection ,  
  
23 
 
the anti coagulant effect  of  the  heparin  is  measured  for   using  
activated  partial thromboplastin time.  This was not required for 
prophylactic heparin use.  However , , ,because of the risks of HIT , 
platelets  should  be  monitored  intermittently  up  to day  14  of  
administration. 
LOW MOLECULAR WEIGHT HEPARIN 
LMWHs  are  made  from  short  chain  polysaccharides  with  a  
molecular  weight  <8KDa.  They  have  the  similar  mode  of action to 
unfractionated heparin ,  but  a more  predictable  dose  response   with  
primarily  anti factor Xa  activity  and  only  limited  anti IIa  activity.  A 
range of products  were  obtained  by various methods of   fractionation 
or   depolymerization  of  heparin   which   include   enoxaparin  
,daltaparin .Tinzaparin ,which  give  varying  chemical , physical  and  
biological  properties.  LMWHs  are  more  effective  at reducing the risk 
of  both  DVT  and  PE  with  the  lower risk of  bleeding,  HIT, 
osteoporosis than  unfractinated heparin.  LMWHs   are cleared by the  
kidneys  and  should  be  used  caution  with  severe renal failure.  Doses 
of  LMWHs  depend  on formulation  but  all  are delivered  as a once 
daily sub cutaneous injection.  LMWHs  require  no laboratory 
monitoring  although  antiXa  assay  can  be used   if  drug administration  
  
24 
 
was  suspected  in cases of  severe renal failure.   Platelets  should  be  
monitored because  of  the   risks  of  HIT  as with  unfractionated 
heparin. 
WARFARIN 
Warfarin  inhibits  production  of  the   vitamin k  dependent  
coagulation factors  II ,VII ,IX , and X in the liver.  Warfarin   must  be 
admininistred  at a dose that minimizes the hazards of  when  comparing  
its DVT  and  PE  prevention  effects  with  LMWH ,  although  major 
differences  in  bleeding  risks have not been determined.  Warfarin  is  
delivered  as  single   oral daily dose ,  which is its main advantage ,   
aiming for an INR of 1.3 to 1.5.   Disadvantages with its use include an 
unpredictable effect an coagulation , delay in reaching the therapeutic 
effect and the potential  drug interactions. Monitoring   is  therefore  
required   every 3 days   until  stable  and  then  weekly. 
DIRECT FACTOR Xa INHIBITORS 
The  first oral  direct  acting   factor Xa inhibitors ,  Rivaroxaban  
and  dabigatran ,  have recently  been  manufactured  offering single daily 
dosing avoiding  the  need  for  the  alternative  parenteral  preparations.  
They  have  no effect on   prothrombin or platelet function .  They  are  
currently  licensed in  the  UK  for use  in DVT prevention  in primary 
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hip and knee arthroplasty.  The anticoagulant effects can be measured 
using the prothrombin  time  although  routine  monitoring   was  not  
required.   Initial  studies  have  suggested  superior  thromboprophylaxis  
to  LMWH  with  similar  bleeding  risks. 
ASPIRIN 
Aspirin is a salicylate  which  irreversibly  inhibits cyclooxygenase 
1   thereby  preventing thromboxane A2 production , which  has  an  
important  role in  platelet aggregation . Aspirin reduces the risk of  DVT 
and PE  compared  with no  prophylaxis   though  its  effect was  
significantly  less  than heparin , with  the similar  increase  risk  of  
major  bleeding.  The optimal dose  has not been determined  and  on its  
own  is  insufficient  for  adequate  DVT prophylaxis. Aspirin is used as a 
single oral daily dose of 75 to 300 mg. However, it is not recommended  
in  any of the major international thromboprophylaxis   guidelines. 
DANAPAROID 
Danaparoid  is  a  heparinoid  mixture ,  which   inhibits factor Xa  
but  is  chemically  distinct from LMWH.  It  is  usually  used  in  patients  
who  had  developed  HIT.  However ,  there  may  be  some  cross  
reactivity  of the  antibody  to this molecule.  It  is  as  effective  as  
LMWH , but  may  induce the higher risk of major bleeding.  These  
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drugs  are  administered  as a  twice daily  as subcutaneous  injection   fo 
r thromboembolism  prophylaxis.  Anti – Xa  assay levels may be used to 
monitor the effect.  However, this is not required routinely.  Platelets  
monitoring  are required for  HIT  because  of  potential  cross  reactivity. 
FONDAPARINUX 
Fondaparinux   is a synthetic  polysaccharide  having  almost  
identical  structures  to the high- affinity binding  site to   antithrombin  
found on heparin.  Its effect appears to be  antithrombin  as an indirect  
inhibitor of  factor Xa.  It  had a   substantially   lower  incidence of   HIT  
compared with LMWHs and  can  be used as  a substitute   in this 
situation.  Fondaparinux   has been demonstrate  to  be  superior  to   
LMWH    in   prevention of   DVT but  with  some  evidence  of a  higher  
incidence  of  major  bleeding , although its significance is yet to be 
established. These drugs are   delivered parenterally as a single daily 
subcutaneous injection. Monitoring  can  be  achieved  through an  anti-
Xa assay.  However, this is not required in  uncomplicated  Treatment  
situation.  
LEPIRUDIN 
Lepirudin is a recombinant  hirudin  is derived  from  yeast cells 
and   is a direct thrombin inhibitor.  It is  used as an anticoagulant in 
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patients who have suspected or  confirmed HIT.  Despite  
thrombocytopenia ,  the risk of thrombosis may be  upto  50 %  unless  an 
anticoagulant is used.  These drugs are   delivered as   continuous 
infusion and  its  activity  is  measured  using   the  aPTT.   Because of  
the  risk  of  thrombosis ,  a ratio of  2.0 to 3.0  is  the target. 
DEXTRANS 
Dextran is   polysaccharide  which , by  adhering  to red blood cells  
and  platelets, reduces  their  adhesiveness.  Additionally , it  enchances 
the effects of antithrombin.  It is  available as different  molecular 
weights (e.g.Dextran 10,40,60and 70.)  which have  additional effects  . 
Volume  expanders  and which  in large volumes provide  dilutional  
antithrombotic effects.  Dextrans  need to be  administered  intravenously 
,  with volumes in excess of 1500 ml required to achieving an 
anticoagulant effect. These  drugs  used  therefore  generally  confined to 
the  intraoperative  period only. The larger  molecules  are resistant  to 
renal excretion and  consequently  retain  their antithrombosis effects  for 
longer.  Side effects include hypersensitivity reactions , fluid overload , 
,and interference with the blood group testing because of red cell 
clumping.  Dextran  is effective  at  reducing  DVT  although  this is  less  
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effective  than other   pharmacological  treatments.  Hence  dextran  is  no 
longer  recommended  for DVT  prophylaxis. 
REGIONAL ANAESTHESIA 
The use of lower limb neuroaxial block , as either a single injection 
or the continuous infusion , has demonstrated  a  significant reduction in 
DVT  formation  compared  with  patients  receiving    general 
anaesthesia  alone.   The REGIONAL ANAESTHESIA  effects  are  an  
improved blood flow through  the  legs  secondary to  sympathectomy- 
induced vasodilatation.  This  is  at  a  time  when  patient  immobility  
and  hypercoagulable state produced  by  the surgical stress  response 
create a high risk  environment  for DVT formation. Consideration  must  
be  given  to  pharmacological dose times  and  neuroaxial  block. 
PATIENT INFORMATION 
Although  an evidence  based  for this mode of prevention  is 
lacking , it is still    recommended   that  healthcare  professionals  offer  
verbal and written information before  surgery.  This  should  be  as  part 
of obtaining  surgical consent ,  detailing  the  risks and the effectiveness 
of prophylaxis . It  may  be  extend  to  information  relevant  on  
discharge  including  signs  and symptoms of DVT and PE , the  correct  
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use of  prophylaxis  at home ,  and potential  implications  of  failure  to  
follow  this  advice . 
PHYSIOTHERAPHY AND NURSING 
Immobility  and  lack of  exercise  are  widely accepted as risk 
factors for developing  DVT . When  normal  lower limb venous pumb   
function  is lost as result of bed rest ,venous stasis manifests itself in two 
ways . First, there is a decrease in  the linear velocity of blood , affecting 
venous return from the lower extremities. Secondly , this decrease in the 
mean flow and pulsation of  the venous flow is  followed by dilatation of  
the vein  delaying  the further venous  return  and  leading to venous 
stasis.  Although  robust  clinical  data   are  lacking , these  risks  can  
potentially  mediated  by  mechanical  calf  and foot venous  compression 
, bed exercise ,  active  or  passive  and  early  mobilization. 
HYDRATION 
Again  clinical  evidence  was  lacking.  However avoidance of  
dehydration in the  perioperative period will attenuate the 
hypercoagulable state produced  after  surgery  and  was  otherwise  good  
patient  management  in  the  majority  of  clinical  situations. 
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CAVAL FILTERS 
Vena caval filters are placed  in the inferior or rarely superior  vena  
cava by  radiologically controlled techniques.  Their purpose  is to 
prevent the embolized  thrombous  from  reaching   the pulmonary 
circulation  and  can be placed as  permanent or temporary retrievable  
filters.  Evidence  for their use in the  hospitalized  patients  is limited  
and  therefore  they  are  recommended  only  for  use  in  patients  who  
have  known   large  proximal  DVT , and who  have  had  an  embolism 
(within 1 month)  and   in whom  anticoagulation  is contraindicated , 
they  are  associated  with  a higher incidence of recurrent  DVTs. 
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ANATOMY OF  VEINS OF  UPPER  AND  LOWERLIMB 
FIGURE 1 
 
                                         FIGURE 2 
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PICTURES OF OUR STUDY POSTOPERATIVE DEEP VEIN  
THROMBOSIS PATIENTS 
FIGURE 3 AND 4 
 
FIGURE 5 AND 6 
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DOPPLER ASSESSMENT PICTURES OF DEEP  
VEIN THROMBOSIS 
FIGURE 7,8 AND 9 
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DOPPLER ASSESSMENT OF POSTOPERATIVE  DVT 
 
  
35 
 
 
  
  
36 
 
MATERIALS AND METHODS 
 
STUDY DESIGN, METHODOLOGY,TECHNIQUES: 
STUDY DESIGN: 
    CASE CONTROL AND CROSS SECTIONAL STUDY 
METHODOLOGY: 
 In hospital  admitted  patients  undergoing   surgery,   Doppler  
assessment of the patients ,  major  abdominal  surgeries  ,   individual  
assessment  of  risk factors favouring   DEEP VEIN THROMBOSIS   for 
the  period of one year in COIMBATORE MEDICAL COLLEGE 
HOSPITAL 
SAMPLE SIZE:   
 N=224   BY 30 PERCENTAGE PREVALENCE RATE. 
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INCLUSION CRITERIA: 
1.  All surgical patients in the age group ABOVE 15 YEARS 
2. All cancer patients 
3. Obesity  
EXCLUSION CRITERIA: 
o Age below 15 years  
o Psychiatric patients 
o Pregnancy 
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RISK FACTOR ASSESSMENT TOOL 
POINTS FACTORS 
1 30 to 40 years of age 
2 40 to 60 years of age 
3 >70 years of age 
2 History of smoking 
2 Cancer patients underwent surgery 
2 Previous history of DVT 
2 Family historyof thrombosis 
2 History of varicose veins 
2 History of chronic medical illness 
2 History of connective tissue disorder 
2 History of underwent the chemo/radiotheraphy 
1 Obesity    25 to 30 BMI 
2 Obesity      30 TO 35 BMI 
3 Obesity        >35 BMI 
1 Spinal anaesthesia 
2 General anaesthesia 
1 30 minutes to 1 hour duration of surgery  
2 1 hour to 3 hour duration of surgery  
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3  > 3 hour duration of surgery  
1 <7 days immobilization period 
2 7 to 14 days immobilization period  
3 > 14 days immobilization period 
 
RISK ASSESSMENT SCORE 
               1 TO 6 LOW RISK GROUPS 
               7 TO 12 MODERATE RISK GROUPS 
              >12 HIGH RISK GROUPS 
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OBSERVATION AND ANALYSIS 
 
TABLE 1 : DVT DISTRIBUTION 
DVT NO OF PATIENTS PERCENTAGE 
PRESENT 47 21% 
ABSENT 177 79% 
 
 
Total number of patients  underwent surgery at CMCH was 224.  Among 
the surgical patients 47 patients developed deep vein thrombosis post 
operatively around 21 percecnt.  And patients not developed Deep vein  
thrombosis post operatively around 79 percent.  Hence in our study 21 
percent prevalence risk positive among the surgical patients. 
 
PRESENT
21%
ABSENT
79%
DEEP VEIN THROMBOSIS
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TABLE 2: AGE DISTRIBUTION 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
< 40 46 21% 
41-60 86 38% 
61-70 63 28% 
>70 29 13% 
 
 
 
In our study 224 patients underwentthe surgery  46 patients comesunder  
less than   46 years age group with   21 percentage  ,  86 patients  comes   
under  40 to 60 years age group with 38  percentage  , 63 patients  comes   
under 60 to70 years age group    with 28  percentage ,   29 patients comes  
under  more than 70 years age group   with  13 percentage. 
 
< 40
21%
41-60
38%
61-70
28%
>70
13%
AGE DISTRIBUTION
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TABLE 3: DVT DISTRIBUTION IN AGE GROUPS 
AGE IN YEARS 
DVT 
PRESENT ABSENT 
< 40 5 41 
41-60 16 70 
61-70 14 49 
>70 12 17 
KRUSKAL WALLIS TEST 
P VALUE - 0.015 
SIGNIFICANT 
 
 
 
  
11%
19% 22%
41%
89%
81% 78%
59%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
<  4 0 4 1 - 6 0 6 1 - 7 0 > 7 0
AGE VS DVT
DVT DVT
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In age group< 40 years patients 5 patients developed DVT post 
operatively among the 46 patients.  In age group  41 to 60 years old 
patients  16 patients developed  DVT  postoperatively among the 86 
patients.  In age group 60 to 70 years patients  14 patients developed  
DVT  post operatively among the 63 patients. 
      In age group > 70 years old patients 12 patients developed 
DVT  among the 29patients.  Finally in our study   > 70 years old patients 
more prone to develop DVT risk patients underwentsurgery with 
prevalence of   46 percent.   KRUSKAL WALLIS test    showed  P value 
of 0.015 with significant result. 
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TABLE 4 : SEX DISTRIBUTION 
SEX NO OF PATIENTS PERCENTAGE 
MALE 159 71% 
FEMALE 65 29% 
 
 
 
 
In our study 224 patients underwent  surgery  159 male  patients with  71 
percentage and  65 female patients  with  29 percentage. 
 
  
71%
29%
SEX DISTRIBUTION
MALE
FEMALE
  
45 
 
TABLE 5 : DVT DISTRIBUTION AND SEX 
SEX 
DVT 
PRESENT ABSENT 
MALE 39 120 
FEMALE 8 57 
CHI SQUARE TEST 
P VALUE - 0.041 
SIGNIFICANT 
 
 
Totally 39 male patients developed DVT  post operatively among the 159 
male  patients . Totally  8 female patients developed   DVT  post 
operatively among the 65 female patients. 
39
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8
57
0
20
40
60
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DVT
SEX VS DVT
MALE FEMALE
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TABLE 6 : BODY MASS INDEX 
BMI NO OF PATIENTS PERCENTAGE 
<25 141 63% 
25-30 39 17% 
30-35 17 8% 
>35 27 12% 
 
 
In our study 224 patients underwent  surgery  141 patients  comes  under  
BMI  of less than 25 with 63 percentage ,  39 patients comes  under   
BMI  of 25 to 30 with 17 percentage , 17 patients comes  under  BMI  of 
30 to 35 with 8 percentage ,  27 patients  comes  under   BMI of  more 
than  35  with  12 percentage. 
 
<25
63%
25-30
17%
30-35
8%
>35
12%
BODY MASS INDEX
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TABLE 7 : DVT DISTRIBUTION ACCORDING TO BMI 
BMI 
DVT 
PRESENT ABSENT 
<25 28 113 
25-30 4 35 
30-35 4 13 
>35 11 16 
KRUSKAL WALLIS TEST 
P VALUE - 0.026 
SIGNIFICANT 
 
 
 
20%
10%
24%
41%
80%
90%
76%
59%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
< 2 5 2 5 - 3 0 3 0 - 3 5 > 3 5
BMI VS DVT
DVT DVT
  
48 
 
 
Patients with  BMI  < 25  around 28  patients  developed  DVT  post  
operatively  among the 141 patients.   Patients with  BMI 25 to 30  
around 4 patients developed DVT post operatively among the 39 patients.  
Patients with  BMI  30 to 35  around 4 patients  developed  DVT post 
operatively  among the   27 patients.  Patients  with BMI  >35  around 
11patients  developed  DVT post operatively   among the  17 patients 
with the prevalence  of 41 percent. Compared to other  BMI ,  morbid  
obese  patients  undergoing  surgery  more  prone  for  DVT  risk  post 
operatively. 
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TABLE 8 : SMOKING PATIENTS 
SMOKING NO OF PATIENTS PERCENTAGE 
PRESENT 128 57% 
ABSENT 96 43% 
 
 
 
 
In our study   224 patients underwent  surgery   128 patients   were  
smokers  with    57 percentage ,   96 patients   were  non smokers with   
43 percentage. 
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TABLE 9 : DVT DISTRIBUTION IN SMOKERS 
SMOKING 
DVT 
PRESENT ABSENT 
PRESENT 36 92 
ABSENT 11 85 
CHI SQUARE TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
Among the  128 patients with smoking history underwent  surgery 36 
patients developed deep vein thrombosis . Chi square test showed  P 
value of  0.001 with significant result .  Hence  in our  study patients  
underwent  surgery  with  smoking  history more  prone to develop the 
DVT post operatively. 
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TABLE 10 : CANCER PATIENTS 
CANCER NO OF PATIENTS PERCENTAGE 
PRESENT 34 15% 
ABSENT 190 85% 
 
 
 
 
Totally  224 patients  underwent  surgery 3 4 cancer patients with 15 
percentage . 190 non cancer patients with 8 5 percentage. 
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TABLE 11 :   DVT DISTRIBUTION AMONG  
CANCER PATIENTS 
CANCER 
DVT 
PRESENT ABSENT 
PRESENT 14 20 
ABSENT 33 157 
CHI SQUARE TEST 
P VALUE - 0.002 
SIGNIFICANT 
 
 
Total number of  14 patients  developed DVT among the cancer patients 
underwent the surgery with the prevalence  of 41 percent.   Hence in our 
study cancer patients underwent  surgery more prone to develop DVT 
risk .  Chi square test showed  P value of 0.002 with significant result. 
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TABLE 12 :  PREVIOUS HISTORY OF DVT PATIENTS 
H/O DVT NO OF PATIENTS PERCENTAGE 
PRESENT 11 5% 
ABSENT 213 95% 
 
 
 
 
 
Among the 224 patients underwent surgery 11 patients had history of 
deep vein thrombosis previously. 
  
5%
95%
H/O DVT
PRESENT
ABSENT
  
54 
 
TABLE 13 :   DVT  DISTRIBUTION  AMONG  PREVIOUS  
HISTORY  OF  DVT  PATIENTS 
H/O DVT 
DVT 
PRESENT ABSENT 
PRESENT 3 8 
ABSENT 44 169 
CHI SQUARE TEST 
P VALUE - 0.599 
NON SIGNIFICANT 
 
 
In our study 224 patients underwent surgery 3 patients developed post 
operative deep vein thrombosis had previous history of deep vein 
thrombosis.  In our study chi square test showed p value of 0.599 with 
non-significant result. In our study patient had previous history of deep 
vein thrombosis less prone for post-operative DVT. These 3 patients had 
other risk factors along with previous history of deep vein thrombosis 
developed  post operative DVT. 
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TABLE 14 : FAMILY HISTORY OF THROMBOSIS PATIENTS 
THROMOBOSIS NO OF PATIENTS PERCENTAGE 
PRESENT 10 5% 
ABSENT 214 95% 
 
 
 
 
In our study 10 patients had previous history of  thrombosis  among the 
224 patients underwent  surgery. 
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TABLE 15 : DVT DISTRIBUTION AMONG THE  
FAMILY HISTORY OF THROMBOSIS PATIENTS 
THROMBOSIS 
DVT 
PRESENT ABSENT 
PRESENT 1 9 
ABSENT 46 168 
CHI SQUARE TEST 
P VALUE - 0.634 
NON SIGNIFICANT  
 
 
 
In our study 10 patients  had the previous history of deep vein thrombosis 
1 patient developed  DVT post operatively.  In our study chi square test 
showed non significant result.  Hence in our hospital this study showed 
previous history of thrombosis patients less likely to develop the DVT 
compared to other risk factors. 
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TABLE 16 : VARICOSE VEINS PATIENTS 
VARICOSE VEINS NO OF PATIENTS PERCENTAGE 
PRESENT 30 14% 
ABSENT 194 86% 
 
 
 
30  patients  had  previous  history  of  varicose  vein  among  the  24  
patients underwent  surgery. 
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TABLE 17 : DVT DISTRIBUTION AMONG THE  
VARICOSE VEIN PATIENTS 
VARICOSE VEINS 
DVT 
PRESENT ABSENT 
PRESENT 6 24 
ABSENT 41 153 
CHI SQUARE TEST 
P VALUE - 0.865 
NON SIGNIFICANT 
 
 
In our study 30 patients had previous history of varicose vein underwent  
surgery  6  patients  developed  deep  vein  thrombosis  post operatively.  
In our study chi square tests  showed  non significant result. Hence in our 
hospital this study showed patients with previous history of varicose vein  
underwent  surgery less likely to develop DVT risk compared to other 
risk factors. 
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TABLE 18 : MEDICAL ILLNESS PATIENTS 
MEDICAL ILLNESS NO OF PATIENTS PERCENTAGE 
PRESENT 44 20% 
ABSENT 180 80% 
 
 
 
 
Totally 44 patients had history of chronic medical illness among the 224 
patients underwent surgery. 
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TABLE 19 : DVT DISTRIBUTION AMONG CHRONIC 
MEDICAL ILLNESS PATIENTS 
MEDICAL ILLNESS 
DVT 
PRESENT ABSENT 
PRESENT 19 25 
ABSENT 25 152 
CHI SQUARE TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
In chronic medical illness patients  underwent  surgery 19 patients 
developed deep vein thrombosis among the 44 patients. Chi square test 
showed  P value of 0.001 with  significant result. Hence in our study 
chronic medical illness  patients underwent  surgery more prone to 
develop the deep vein thrombosis  risk with prevalence of  43 percentage. 
19 2525
152
0
20
40
60
80
100
120
140
160
PRESENT ABSENT
DVT
MEDICAL ILLNESS VS DVT
MALE FEMALE
  
61 
 
TABLE 20 : CONNECTIVE TISSUE DISORDER PATIENTS 
CTD NO OF PATIENTS PERCENTAGE 
PRESENT 9 4% 
ABSENT 215 96% 
 
 
 
 
9 patients had the connective tissue disorder history among the 224 
patients underwent surgery. 
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TABLE 21 : DVT DISTRIBUTION AMONG CONNECTIVE 
TISSUE DISORDER PATIENTS 
CTD 
DVT 
PRESENT ABSENT 
YES 1 8 
NO 46 167 
CHI SQUARE TEST 
P VALUE - 0.661 
NON SIGNIFICANT 
 
 
Among the connective tissue disorder patients underwent the surgery 1 
patient developed  DVT post operatively. Chi square test showed non 
significant result.  Hence in our study connective tissue disorder patients 
underwent surgery less likely to develop deep vein thrombosis risk  post 
operatively.  
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TABLE 22 : CHEMO/RADIOTHERAPY RECEIVED PATIENTS 
CHEMO/RADIOTHERAPY NO OF PATIENTS PERCENTAGE 
YES 8 4% 
NO 216 96% 
 
 
 
 
Among the 224 patients underwent surgery 8 patients received  
chemotheraphy /rdaiotheraphy with  4 percentage . 
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TABLE 23 : DVT DISTRIBUTION AMONG CHEMO / 
RADIOTHERAPHY RECEIVED PATIENTS 
CHEMO/RADIOTHERAPY 
DVT 
PRESENT ABSENT 
YES 5 3 
NO 42 174 
CHI SQUARE TEST 
P VALUE - 0.003 
SIGNIFICANT 
 
 
Among the chemotheraphy/radiotheraphy received patients 5 patients 
developed DVT  Post Operatively. Chi square test showedp value of 
0.003 with significant result.  Hence in our study chemotheraphy/ 
radiotheraphy  received  patients  significantly  associated  with the post 
operative DVT risk. 
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TABLE 24 : SPINAL ANAESTHESIA  
SPINAL ANAESTHESIA NO OF PATIENTS PERCENTAGE 
YES 102 46% 
NO 122 54% 
 
 
 
 
Among  the  224  patients  102  patients  underwent  surgery  with  spinal 
anaesthesia. 
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TABLE 25 : DVT  DISTRIBUTION  AMONG  PATIENTS 
UNDERWENT  SURGERY  WITH  SPINAL  ANAES THESIA 
SPINAL ANAESTHESIA 
DVT 
PRESENT ABSENT 
YES 15 87 
NO 32 90 
CHI SQUARE TEST 
P VALUE - 0.035 
SIGNIFICANT 
 
 
 
In our study 15 patients developed deep vein thrombosis post operatively 
among the 102 patient  underwent  surgery  with  spinal anaesthesia .  Chi 
square test showed P value  of  0.035 with significant result.  Hence in 
our study patients  underwent  the surgery with spinal anaesthesia  more 
prone to develop deep  vein  thrombosis  post operatively. 
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 TABLE 26 : GENERAL ANAESTHESIA  
GENERAL ANAESTHESIA NO OF PATIENTS PERCENTAGE 
YES 122 5% 
NO 102 46% 
 
 
 
 
Among 224 patients  underwent  the surgery 122 patients  underwent  
surgery with general anaesthesia  with 54 percentage. 
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TABLE 27 : DVT  DISTRIBUTION  AMONG  PATIENTS 
UNDERWENT  SURGERY  WITH  GENERAL  ANAES THESIA 
GENERAL ANAESTHESIA 
DVT 
PRESENT ABSENT 
YES 32 90 
NO 15 87 
CHI SQUARE TEST 
P VALUE - 0.034 
SIGNIFICANT 
 
 
 
In our study 32 patients developed deep vein thrombosis post operatively 
among the  122 patient   underwent  surgery with general anaesthesia . 
Chi square test showed  P value of 0.034 with significant result.  Hence 
in our study patients underwent the surgery with  general  anaesthesia  
more prone to develop deep  vein  thrombosis  post operatively. 
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 TABLE 28 : DURATION OF SURGERY  
DURATION OF SURGERY NO OF PATIENTS PERCENTAGE 
30 MIN -1 HR 114 51% 
1-3 HR 93 41% 
> 3 HR 17 8% 
 
 
 
Among the 224  patients  underwent  surgery  114 patients  underwent  
surgery with duration of  30 minutes to1 hour.  93 patients  underwent  
surgery with duration of  1hour to 3 hour.  17 patients  underwent surgery 
with duration of   more than 3 hours. 
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TABLE 29 : DVT  DISTRIBUTION  AND   
DURATION  OF SURGERY 
DURATION OF SURGERY 
DVT 
PRESENT ABSENT 
30 MIN -1 HR 13 101 
1-3 HR 25 68 
> 3 HR 9 8 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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13 patients developed deep vein thrombosis with the duration of  surgery  
30 minutes to 1 hour among the 114 patients . 25 patients developed deep 
vein thrombosis with the duration of surgery  1 hour to 3 hour among the  
93 patients.  9 patients developed  deep vein thrombosis  with duration of 
surgery more than  3 hours among the  17 patients . KRUSKAL WALLIS  
test showed p value of 0.001 with significant result.  Hence in our study  
patients underwent  surgery  with  more than 3 hours duration 
significantly associated with post operative deep vein thrombosis risk 
with prevalence of 53 percentage. 
 
  
  
72 
 
  TABLE 30 : IMMOBILISATION DAYS 
IMMOBILISATION DAYS NO OF PATIENTS PERCENTAGE 
< 7 DAYS 146 65% 
7-14 DAYS 53 24% 
>14 DAYS 25 11% 
 
 
 
 
Among the 224 patients underwent  surgery 146 patients had less than 7 
days immobilization. 53 patients had 7 to 14 days immobilization. 25 
patients hadmore than 14 days immobilization. 
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TABLE 31 : DVT DISTRIBUTION AND  
IMMOBILIZATION DAYS  
IMMOBILISATION DAYS 
DVT 
PRESENT ABSENT 
< 7 DAYS 18 128 
7-14 DAYS 12 41 
>14 DAYS 17 8 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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18 patients developed DVT post operatively patients had  less than 7 days 
immobilization among 146 patients. 5 patients had 7 to 14 days  
immobilization post operatively  developed  DVT  among 53 patients. 17 
patients had immobilization more than  14 days post operatively 
developed DVT among the  25 patients.  KRUSKAL WALLIS test 
showed p value of 0.001 with significant result.  Hence in our study 
showed  patients  underwent  surgery with more than 14 days 
immobilization significantly associated with post operative deep vein 
thrombosis risk with prevalence of  68 percentage. 
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TABLE 32 : DVT RISK SCORE  
RISK SCORE NO OF PATIENTS PERCENTAGE 
LOW RISK (1-6) 90 40% 
MODERATE RISK 
(7-12) 
75 33% 
HIGH RISK (>12) 59 27% 
 
Among the 224 patients underwent  surgery 90 patients  under the low 
risk group. 75 patients under the moderate risk group. 59 patients under 
the high risk group. 
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TABLE 33 : DVT DISTRIBUTION AMONG LOW , MODERATE , 
HIGH RISK GROUP PATIENTS  
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RISK SCORE 
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PRESENT ABSENT 
LOW RISK (1-6) 8 82 
MODERATE RISK (7-12) 16 59 
HIGH RISK (>12) 23 36 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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In  patients underwent  surgery with low risk  group 8 patients developed 
deep vein thrombosis among 90 patients.  Moderate risk group, 16 
patients developed deep vein thrombosis among 65 patients.  High risk 
group, patients 23 patients developed deep vein thrombosis among 59 
patients.  UN PAIRED T TEST showed p value of 0.001 with significant 
result.   Hence in our study high risk group patients  underwent  surgery 
significantly associated with post operative risk  of DVT with the 
prevalence of 39 percentage.  
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TABLE 34 : MEAN RISK SCORE VS DVT 
DEEP VEIN THROMBOSIS 
RISK SCORE 
MEAN SD 
PRESENT(47) 11.87 3.75 
ABSENT(177) 8.16 3.64 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
 
In our study totally 224 patients underwent surgery 47 patients developed 
the post operative  DEEP  VEIN THROMBOSIS  with overall 21 
percentage. 
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DISCUSSION 
DVT is a common cause of preventable hospital mortality.  DVT 
occurring after general surgery is a common pathology in the absence of  
specific prophylaxis with significant morbidity and  mortality  and high 
socioeconomic costs. This study assessed the potential of  several 
parameters to be risk factors contributing to the occurrence of DEEP 
VEIN THROMBOSIS  of the lower limbs  after general surgery for the 
patients without preoperative DVT  prophylaxis. 
Approximately 50 % of all cases of calf  deep vein  thrombosis are 
self-limiting and  resolve within the first 72 hours  after surgery , 40 % 
remain in calf , and 10 % progress to proximal vein thrombosis , which 
greatly increases the risk of pulmonary embolism. The risk of   DEEP 
VEIN THROMBOSIS is different depending on the type of surgery 
performed. Surgicalinterventions such as laparoscopic cholecystectomy , 
appendectomy , transurethral prostatectomy or mastectomy have the 
lower risk of developing DVT.  Various previous studies revealed 
general surgery had a 15 to 30 % risk of developing  DVT  in the absence 
of anticoagulant or mechanical prophylaxis. 
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In our study totally 47 patients developed DEEP  VEIN 
THROMBOSIS post operatively among the 224 patients underwent 
surgery without thromboembolism prophylaxis with prevalence of 21 
percentage . Various risk factors analysed  and needed for pre-operative 
thromboembolism prophylaxis documented below. 
In our review of literature showed high risk group patients with 
risk factors of previous history of cancer ,chronic medical illness, 
previous history of varicose vein ,obesity , smoking , prolonged duration 
of surgery , chronic immobilization days  were developed  DEEP VEIN 
THROMBOSIS with  39 percentage .  Moderate risk group patients with 
risk factors of age , smoking , obesity , cancer patients , duration of 
surgery  and immobilization days were developed  DEEP VEIN 
THROMBOSIS with 21 percentage.   Low risk group patients were 
developed  DEEP VEIN THROMBOSIS  with  8 percentage . 
According to our study old age more than 70 year patients 
underwent surgery more prone to develop DVT after surgery . Obesity  
and  smoking  major predisposing factors for DVT  post operatively. 
Morbid obese patients and chronic smoking history patients significantly 
associated with the development of DVT postoperatively.  In our study 
cancer patients ,  chronic medical illness patients , post operatively 
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prolonged immobilization patients were significantly associated with 
development of  DEEP VEIN THROMBOSIS post operatively.Hence 
these patients , moderate and high risk group patients  definitely require 
the preoperative thromboembolism prophylaxis in order to prevention of 
post operative DEEP VEIN THROMBOSIS. 
The ACCP guidelines highlight 2 approaches to decision  making  
withregard to thromboembolism prophylaxis. The first is to consider the 
risk of DVT in each patients based on their individual predisposing 
factors and the risk associated with their current illness or procedure , 
with the use of prophylaxis based on the composite risk estimate.  A 
second approach , favoured  by  the ACCP , is to implement group 
specific prophylaxis  for all patients who belong to one of several major 
target groups (eg , type of surgery , age , and presence of additional risk 
factors). 
A simplified approach to estimating an individual patient’s risk , 
based on the presence of both predisposing  and exposing  (in hospital) 
risk factors , might provide a suitable way to ascertain a patient’s risk of 
DEEP VEIN THROMBOSIS.  Such a system would allocate the patients 
with a reasonable measure  of  low , moderate , or high risk groups so 
that prophylaxis could be tailored to the element of risk that the patient is 
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facing.  Highly  safe  and effective types of DVT prophylaxis include low 
molecular weight heparin ,warfarin , intermittent pneumatic compression 
and low dose unfractionated heparin. If patients contraindication for 
DEEP VEIN THEOMBOSIS prophylaxis   ( active bleeding , history of 
heparin induced thrombocytopenia , a platelet count less than 1,00,000 or 
platelet inhibitors , or abnormal creatinine clearance rate ) intermittent 
pneumatic compression should be considered. 
Various studies showed use of pre-operative thromboembolism 
prophylaxis significantly reduced mortality and morbidity of post-
operative deep vein thrombosis.According to our study  showed  any  
patient underwent the surgery  needed for evaluation of individual risk 
factors and usage of pre-operative thromboembolism prophylaxis in order 
to prevent the post operative DEEP VEIN THROMBOSIS.  
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CONCLUSION 
Pulmonary embolism is the most common preventable cause of 
death among hospital patients.  DVT is often overlooked as  major public 
health problem and viewed as complication of hospitalization for another 
illness rather than a specific diseases entity. 
The prevalence and prevention of DEEP VEIN THROMBOSIS 
has historically been poorly recognized and lacked clinical status. This is 
changing with greater public awareness , clinician and nursing education 
, in high profile publication of risk assessments , and national guidelines 
and preventive measures.  Evidence is now emerging that DVT risks 
extend  6 to 12 weeks post surgery in the presence of certain  risk  
factors. This evidence  may  impact  further on recommended  duration of 
prophylaxis  for targeted group  in future  DVT guidelines. 
The potential public health benefit of  DVT is substantial:data from 
randomized trials involving general surgical patients suggest that 
adequate prophylaxis in high risk patients can prevent DVT in 1 of 10 
patients and save the life of  1 of 200 patients.  In our study also  showed 
moderate  and high risk group patients underwent surgery definitely 
needed  thromboprophylaxis  pre operatively and  6 to 12  weeks of 
postoperative period for prevention of postoperative  DVT. 
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PROFORMA 
NAME :                                                   UNIT  NO :  
I.P.NO: 
AGE /SEX: 
OCCUPATION :                     DATE OF ADMISSION : 
 
ADDRESS:              DATE OF DISCHARGE:  
 
CONTACT NO: 
 
DIAGNOSIS: 
PROCEDURE DONE :  
PARAMETERS    
 AGE 
 OBESITY 
 SMOKING 
 CANCER PATIENTS 
 PREVIOUS HISTORY OF DEEP VEIN  THROMBOSIS 
 FAMILY HISTORY OF THROMBOSIS 
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 PREVIOUS HISTORY OF VARICOSE VEIN 
 CHRONIC MEDICAL ILLNESS 
 HISTORY OF CONNECTIVE TISSUE DISORDER 
 CHEMO/ RADIOTHERAPHY RECEIVED PATIENTS 
 SPINAL/ GENERAL ANAESTHESIA 
 DURATION OF SURGERY 
 IMMOBILIZATION DAYS 
 
TOTAL RISK SCORE : 
 
POST OPERATIVE FOLLOW UP : 
 
OUTCOME: 
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xg;g[jy; gotk;  
 
bgah;  -  
ghypdk;  -  
Kfthp - taJ -  
 muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ mWit rpfpr;ir 
Jiwapy;/ gl;lnkw;gog;g[ gapYk; khzth; nt. n$hjp ehuhazrhkp 
mth;fs; nkw;bfhs;Sk; ASSESSMENT OF RISK FACTORS 
FAVOURING DEEP VEIN THROMBOSIS IN PATIENTS  
UNDERGOING SURGERY vd;w nrhjidapd; bra;Kiw kw;Wk; 
midj;J tpgu';fisa[k; nfl;Lf; bfhz;lJld;/ vdJ midj;J 
re;njf';fisa[k; bjspt[gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf; 
bfhs;fpnwd;.  
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;.  
 ,e;j Ma;tpy; vd;Dila midj;J tpgu';fSk; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; 
vdf;F ve;j Ml;nrgida[k; ,y;iy vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
ve;j neuj;jpYk; ,e;j Ma;tpy; ,Ue;J tpyfpf; bfhs;s vdf;F chpik 
cz;L vd;gija[k; mwpntd;.  
 
,lk; -  
njjp -  
ifbahg;gk;/ nuif  
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MASTER CHART 
S.No Name Gender Age BMI Smoking Cancer DVT Thrombosis Varicose vein 
Medical 
illness CTD 
Chemo 
or RT Spinal General 
Duration 
of surgery 
Immobilization 
days 
Risk 
score 
1 Subbiah M 0 1 2 0 0 0 0 0 0 0 1 0 1 1 6 
2 Velmurugan M 1 1 2 0 0 0 0 2 0 0 1 0 1 1 9 
3 Saraswathi F 0 1 0 0 0 0 0 0 0 0 1 0 1 1 4 
4 Arumugam M 0 1 2 0 0 0 0 0 0 0 1 0 1 1 6 
5 Subramani M 1 2 2 0 0 0 0 2 0 0 0 2 2 2 13 
6 Aadhi M 0 1 2 0 0 0 0 0 0 0 1 0 1 1 6 
7 Kannagi F 0 1 0 0 0 0 0 0 0 0 0 2 2 1 6 
8 Manimozhi F 0 1 0 0 0 0 0 0 0 0 1 0 1 1 4 
9 Velan M 1 1 0 0 0 0 0 0 0 0 1 0 1 1 5 
10 Kandhasamy M 2 1 2 0 0 0 0 2 0 0 0 2 2 2 13 
11 Palani M 1 1 2 0 0 0 2 0 0 0 1 0 1 1 9 
12 Kathir M 1 0 2 0 0 0 0 0 0 0 0 2 2 1 10 
13 Mani M 1 0 2 0 0 0 0 0 0 0 1 0 1 1 6 
14 Karthi M 0 0 0 0 0 0 0 0 0 0 1 0 0 1 2 
15 Balan M 1 0 2 0 0 0 0 0 0 2 0 2 2 2 11 
16 Surya M 1 0 2 2 0 0 0 0 0 2 0 2 2 2 13 
17 Kumaran M 1 0 2 0 0 0 0 2 0 0 0 2 2 2 11 
18 Baiamurugan M 2 0 2 0 0 0 0 2 0 0 1 0 1 1 9 
19 Muniyandi M 1 3 2 0 0 0 0 2 0 0 1 0 1 1 11 
20 Alagammal F 1 0 0 0 0 0 0 0 0 0 0 2 2 1 6 
21 Kabilan M 0 2 2 0 0 0 0 0 0 0 1 0 1 1 7 
22 Ayusha F 0 0 0 0 0 0 0 0 0 0 0 2 2 1 5 
23 Kathiravan M 1 2 0 0 0 0 0 0 0 0 1 0 1 1 6 
24 Rhagavan M 1 0 2 0 0 0 0 0 0 0 1 0 1 1 6 
25 Vellaisamy M 2 2 2 2 0 0 0 0 0 0 0 2 2 3 15 
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26 Saminathan M 0 0 0 0 0 0 0 0 0 0 1 0 0 1 2 
27 Guru M 2 3 2 0 0 0 0 0 0 0 0 2 2 1 12 
28 Selvam M 2 0 2 0 0 0 0 0 0 0 1  1 1 7 
29 Nalini F 2 0 0 0 0 0 0 0 0 0 0 2 1 1 6 
30 Subban M 2 0 2 2 0 0 0 0 0 0 0 2 2 3 13 
31 Mukundan M 2 1 2 2 0 0 0 0 0 0 0 2 2 2 13 
32 Kannan M 3 0 2 2 0 0 0 0 0 0 0 2 3 2 14 
33 Velan M 2 1 2 0 0 0 2 2 0 0 1 0 1 2 13 
34 Arasan M 2 0 2 0 2 0 0 0 0 0 0 2 2 1 11 
35 Sundari F 2 1 0 0 0 2 0 0 0 0 1 0 1 1 8 
36 Dhivyalakshmi F 3 0 0 0 0 0 0 0 2 0 0 2 2 2 11 
37 Senthil M 0 0 2 0 0 0 0 0 0 0 0 2 2 2 8 
38 Kala F 1 1 0 0 0 0 0 0 0 0 1 0 1 1 5 
39 Arun M 2 3 2 0 0 0 0 0 0 0 1 0 1 1 10 
40 Kumar M 1 1 0 0 0 0 0 0 0 0 0 2 2 1 7 
41 lakshmi F 1 0 0 0 0 0 0 0 0 0 0 2 2 1 6 
42 Vinoth M 3 0 2 0 0 0 0 0 0 0 0 2 2 3 12 
43 Nallathambi M 1 0 0 0 0 0 0 0 0 0 0 2 2 1 6 
44 Durai M 0 0 2 0 0 0 0 0 0 0 0 2 2 1 7 
45 Kuppan M 2 0 0 0 0 0 0 0 0 0 1 0 1 1 5 
46 Manoharan M 1 0 2 0 0 0 0 0 0 0 1 0 1 1 6 
47 Priya F 1 1 0 0 0 0 0 0 0 0 0 2 2 1 7 
48 Dhandapani M 2 0 2 2 0 0 0 0 0 0 0 2 3 2 13 
49 Dharshini F 1 0 0 0 0 0 0 0 0 0 1 0 1 1 4 
50 Chinnasamy M 2 0 2 0 0 0 2 0 0 0 0 2 2 1 11 
51 Lavanya F 0 0 0 0 0 0 0 0 0 0 1 0 0 1 2 
52 `Andavar` M 3 0 2 0 0 0 0 2 0 0 0 2 2 3 14 
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53 Chandran M 2 0 2 2 0 0 0 0 0 0 0 2 3 2 13 
54 Muthu M 2 0 2 2 0 0 0 2 0 0 0 2 3 2 15 
55 Rajan M 1 1 2 0 0 0 0 0 0 0 1 0 1 1 7 
56 Jothimuruga M 1 0 2 0 0 0 0 2 0 0 0 2 2 2 11 
57 Devi F 1 1 0 0 0 0 0 0 0 0 1 0 1 1 5 
58 Ramu M 0 1 2 0 0 0 0 0 0 0 1 0 1 1 6 
59 kesavan M 1 0 0 0 0 0 0 0 0 0 0 2 2 1 6 
60 Shagundala F 2 2 0 0 0 0 0 2 0 0 0 2 2 2 12 
61 Babu M 0 0 2 0 0 0 0 0 0 0 0 2 2 2 8 
62 Duraimurugan M 1 0 2 2 0 0 0 0 0 2 0 2 3 3 15 
63 Duraisamy M 3 0 2 0 0 0 2 2 0 0 0 2 2 2 15 
64 Vimal M 2 3 2 0 0 0 0 2 0 0 1 0 1 1 12 
65 velathal F 1 0 0 0 0 0 2 0 0 0 0 2 2 1 8 
66 Kamal M 1 0 0 0 0 0 0 0 0 0 0 2 2 1 6 
67 Kannadhasan M 1 0 0 0 0 0 2 0 0 0 1 0 1 1 6 
68 Parimala F 0 0 0 2 0 0 0 0 0 0 0 2 2 1 7 
69 Venu M 0 0 0 0 0 0 0 0 0 0 0 2 2 1 5 
70 Gopal M 1 0 2 0 0 2 0 0 0 0 1 0 1 1 8 
71 Malar devi F 0 0 0 0 0 0 0 0 0 0 0 2 0 1 3 
72 Eswari F 1 1 0 0 0 0 0 0 0 0 1 0 1 1 5 
73 Arjun M 0 0 2 0 0 0 0 0 0 0 1 0 1 1 5 
74 Ankit M 1 0 2 2 0 0 0 2 0 0 1 0 0 1 9 
75 Gonath M 0 0 2 2 0 0 0 0 0 0 0 2 2 2 10 
76 Angathal F 1 3 0 0 0 0 0 2 0 0 1 0 1 1 9 
77 Amir M 1 0 2 2 0 0 0 2 0 0 0 2 3 2 14 
78 Chokkan M 2 1 2 0 0 0 2 0 0 0 0 2 2 2 13 
79 Saran M 2 0 2 0 0 0 2 0 0 0 0 2 2 2 12 
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80 Raj M 1 3 2 0 2 0 0 0 0 0 1 0 1 1 11 
81 Dhina M 1 3 2 0  0 2 0 0 0 1 0 1 3 13 
82 Raman M 1 0 2 0 0 0 0 0 0 0 1 0 1 1 6 
83 Selvi F 0 0 0 0 0 0 0 0 0 0 0 2 1 1 4 
84 Moorthi M 2 0 0 0 0 0 0 0 0 0 0 2 2 1 7 
85 Karthikeyan M 1 0 2 2 0 0 0 2 0 0 0 2 2 3 14 
86 Perumal M 3 1 2 0 0 0 0 0 0 0 0 2 2 1 11 
87 Nandu M 1 1 2 0 0 0 0 0 0 0 1 0 0 1 6 
88 Kalan M 0 0 0 0 0 0 0 0 0 0 0 2 2 1 5 
89 Balamurugan M 1 0 2 0 0 2 0 0 0 0 1 0 1 1 8 
90 Ramaya F 3 0 2 2 0 0 0 2 0 0 1 0 2 2 14 
91 Leela F 1 2 0 0 2 0 0 0 0 0 0 2 2 2 11 
92 Mariyammal F 2 0 0 0 0 0 0 0 0 0 1 0 1 1 5 
93 Sekar M 1 0 0 0 0 0 0 0 0 0 0 2 2 2 7 
94 Vijay M 0 2 2 0 2 0 0 0 0 0 0 2 3 2 13 
95 Nagasamy M 3 0 2 0 0 0 0 2 0 0 1 0 1 1 10 
96 Praveen M 2 0 2 0 0 0 0 0 0 0 1 0 0 1 6 
97 Gayathri F 2 0 0 0 0 0 0 0 0 0 1 0 1 1 5 
98 Velu M 1 3 2 0 0 0 0 2 0 0 0 2 2 3 15 
99 Niranjan M 1 0 2 2 0 0 0 0 0 2 0 2 2 2 13 
100 Ashwin M 0 0 2 0 0 0 2 0 0 0 1 0 1 1 7 
101 Velusamy M 3 0 2 0 0 0 0 2 0 0 1 0 2 3 13 
102 Palanivelu M 2 0 2 2 0 0 0 2 0 0 0 2 3 3 16 
103 Malar F 0 0 0 0 0 0 0 0 0 0 1 0 1 1 3 
104 Vinay M 1 1 2 0 2 0 0 0 0 0 0 2 2 2 12 
105 Arul M 1 0 0 0 0 0 0 0 0 0 0 2 1 1 5 
106 Velappan M 3 0 2 0 0 0 0 2 0 0 0 2 2 2 13 
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107 Sheela F 3 0 0 2 0 0 0 0 0 0 1 0 1 1 8 
108 Rangasamy M 1 0 0 0 0 0 2 0 0 0 1 0 1 1 6 
109 Elango M 1 3 2 0 0 0 2 0 0 0 0 2 2 3 15 
110 Devaki F 0 0 0 0 2 0 0 0 0 0 1 0 1 1 5 
111 Sundhar M 1 2 0 0 0 0 0 0 0 0 1 0 1 1 6 
112 Ayyammal F 0 0 0 0 0 0 0 0 0 0 0 2 2 2 6 
113 Michael M 0 3 2 0 0 0 2 2 0 0 1 0 2 2 14 
114 Saral F 0 1 0 0 0 0 0 0 0 0 0 2 2 1 6 
115 Surumoorthi M 0 2 2 0 0 0 2 0 0 0 1 0 1 1 9 
116 Kabilnath M 1 1 0 0 0 0 0 0 0 0 1 0 1 1 5 
117 Kalyani F 2 0 0 0 0 2 0 0 0 0 0 2 2 1 9 
118 Janaki F 2 1 0 0 0 0 0 0 0 0 1 0 1 1 6 
119 Mahalakshmi F 3 0 0 2 0 0 0 0 0 2 0 2 2 3 14 
120 Raguvaran M 1 0 2 0 0 0 0 0 2 0 1 0 1 1 8 
121 Muniyammal F 3 0 0 0 0 0 0 0 0 0 1 0 0 1 5 
122 Appasamy M 1 0 2 0 0 0 0 0 0 0 0 2 3 3 11 
123 Palaniyammal F 2 0 0 0 0 0 0 0 0 0 0 2 1 1 6 
124 Ramanan M 1 0 0 0 0 0 0 0 0 0 0 2 2 2 7 
125 Lalitha F 3 0 0 0 0 0 0 0 0 0 1 0 1 1 6 
126 vellaiyappan M 3 0 2 0 0 0 2 0 0 0 0 2 3 3 15 
127 Chenniyappan M 2 2 2 2 0 0 0 2 0 0 0 2 2 2 16 
128 Manivasakan M 1 3 2 0 0 0 2 0 0 0 0 2 2 2 14 
129 Krishna M 1 2 2 0 0 0 0 0 0 0 1 0 1 1 8 
130 Monisha F 0 0 0 0 0 0 0 0 0 0 1 0 0 1 2 
131 Neelakandan M 1 0 2 0 0 0 0 0 0 0 1 0 1 1 6 
132 Rajarajan M 3 0 2 2 0 0 2 0 0 0 0 2 3 2 16 
133 Jegan M 1 3 2 0 0 0 2 0 0 0 1 0 1 1 11 
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134 Parvathi F 3 0 0 0 0 0 0 0 0 0 1 0 1 1 6 
135 Gugan M 1 3 2 0 0 0 0 0 2 0 0 2 2 1 13 
136 Mohan M 2 0 2 2 0 0 0 0 0 2 0 2 3 3 16 
137 Surveshvaran M 1 0 2 0 2 0 0 0 0 0 0 2 2 2 11 
138 Chandra F 1 0 0 0 0 0 0 0 0 0 1 0 1 1 4 
139 Akilan M 0 0 2 0 0 0 0 0 0 0 0 2 1 1 6 
140 Kathiresh M 1 2 2 0 0 0 0 0 2 0 0 2 2 1 12 
141 Palanal F 2 0 0 0 0 0 0 0 0 0 1 0 1 1 5 
142 Shanmugam M 2 3 2 0 0 0 0 2 0 0 0 2 2 2 `              15 
143 Abishek M 1 3 2 0 0 0 2 0 0 0 1 0 2 2 13 
144 Valliyammal F 2 1 0 0 2 0 0 0 0 0 0 2 2 1 10 
145 Noorjahan F 2 1 0 0 0 0 0 0 0 0 1 0 1 1 6 
146 Narmatha F 0 2 0 0 0 2 0 0 0 0 1 0 1 1 7 
147 Suresh M 1 0 0 0 0 0 0 0 0 0 1 0 1 1 4 
148 Ravi M 2 3 2 0 0 0 0 2 0 0 0 2 2 3 16 
149 Gunalan M 1 2 2 0 0 0 0 0 2 0 1 0 1 1 10 
150 Bhuvana F 3 0 0 0 0 0 0 0 0 0 1 0 1 1 6 
151 Maheshwaran M 0 0 2 0 0 0 0 0  0 0 2 2 1 7 
152 Kali M 1 0 0 0 0 0 0 0 0 0 1 0 1 1 4 
153 Shilba F 0 0 0 0 0 0 0 0 0 0 0 2 2 1 5 
154 Jeyakumar M 2 3 2 0 0 0 0 0 0 0 0 2 2 2 13 
155 Murugavel M 2 3 2 0 0 0 0 0 0 0 0 2 2 1 12 
156 Kuppusamy M 1 0 2 0 0 0 2 0 0 0 1 0 1 1 8 
157 Bose M 2 0 2 0 0 0 0 2 0 0 1 0 1 1 9 
158 Ilakkiyan M 0 0 2 0 0 0 0 0 0 0 1 0 1 1 5 
159 Selvaraj M 1 3 2 0 0 0 2 2 0 0 0 2 2 2 16 
160 Venkatachalam M 2 0 2 0 0 0 2 0 0 0 0 2 3 3 14 
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161 Faritha F 1 0 0 0 0 0 0 0 0 0 0 2 1 1 5 
162 Shankar M 3 0 2 2 0 0 0 2 0 0 0 2 2 3 16 
163 Giri M 3 0 2 2 0 0 0 2 2 0 0 2 3 3 19 
164 Fathima F 1 0 0 0 0 0 0 0 0 0 1 0 1 1 4 
165 Karunaiyappan M 2 3 2 0 0 0 2 2 0 0 0 2 2 2 17 
166 Nikil M 2 0 2 0 0 0 0 0 0 0 0 2 2 1 9 
167 Moolan M 1 0 2 2 0 0 0 2 0 0 1 0 1 1 10 
168 Aadhi M 1 3 2 0 0 0 2 0 0 0 0 2 2 2 14 
169 Poomika F 2 0 0 0 0 0 0 0 0 0 0 2 1 1 6 
170 Saravanan M 1 0 0 0 0 0 0 0 0 0 1 0 0 1 3 
171 Bhuvaneshwari F 2 0 0 2 0 0 0 0 0 0 0 2 3 3 12 
172 Kumaravel M 0 0 0 0 0 0 0 0 0 0 1 0 1 1 3 
173 Shreedevi F 1 0 0 0 0 0 0 0 0 0 0 2 1 1 5 
174 Pandi M 3 0 2 2 0 0 0 2 0 0 0 2 2 2 15 
175 Vignesh M 2 1 2 0 2 0 0 0 0 0 0 2 2 2 13 
176 Santhosh M 2 1 2 0 0 0 0 0 2 0 1 0 1 1 10 
177 Sanjay M 1 0 2 0 0 0 0 0 0 0 1 0 1 1 6 
178 Lakshmanan M 2 0 0 0 0 0 0 0 0 0 0 2 1 1 6 
179 Prakash M 1 1 2 0 0 0 0 0 0 0 0 2 2 1 9 
180 Neela F 1 1 0 0 0 0 0 0 0 0 1 0 1 1 5 
181 Ramamoorthi M 2 3 0 0 0 2 0 0 0 0 0 2 2 2 13 
182 Poorvika F 0 0 0 0 0 2 0 0 0 0 0 2 1 1 6 
183 Shreekala F 1 0 0 0 0 0 0 2 0 0 1 0 1 1 6 
184 Ramasamy M 3 0 2 2 0 0 0 0 0 0 0 2 2 2 13 
185 Senthinathan M 2 3 2 0 0 0 0 2 0 0 1 0 1 1 12 
186 Kulanthaiyappan M 2 2 2 0 0 0 0 2 0 0 1 0 1 1 11 
187 Ragav M 2 0 0 0 0 0 0 0 0 0 1 0 1 1 5 
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188 Nayaki F 0 0 0 0 2 0 0 0 0 0 1 0 1 1 5 
189 Thiyagarajan M 2 1 2 2 0 0 0 0 0 2 0 2 2 2 15 
190 Alwin M 2 0 0 0 0 0 0 0 0 0 1 0 0 1 4 
191 Ayyanar M 3 1 2 0 0 0 2 2 0 0 0 2 2 3 17 
192 Revathi F 2 0 0 0 0 0 0 0 2 0 0 2 2 2 10 
193 Renukadevi F 3 0 0 0 0 0 0 0 0 0 1 0 1 1 6 
194 Prasath M 1 3 2 0 0 0 2 2 0 0 0 2 2 2 16 
195 Rangal F 2 0 0 0 0 0 0 2 0 0 0 2 2 2 10 
196 Mangai F 1 0 0 0 0 0 0 0 0 0 1 0 1 1 4 
197 Sathasivam M 3 0 2 0 0 0 0 0 0 0 1 0 1 1 8 
198 Sivaraj M 2 0 2 2 0 0 0 0 0 0 0 2 3 3 14 
199 Selvan M 0 3 2 0 0 0 0 0 0 0 1 0 2 1 9 
200 Murali M 1 0 2 0 0 0 0 0 0 0 1 0 1 1 6 
201 Srinivasan M 3 0 2 2 0 0 0 0 0 0 0 2 3 3 15 
202 Dhenna M 0 0 0 0 0 2 0 0 0 0 1 0 1 1 5 
203 Yamini F 0 0 0 0 0 0 2 0 0 0 1 0 0 1 4 
204 Muneeshwaran M 0 0 0 0 0 0 2 0 0 0 0 2 1 1 6 
205 Valarmathi F 0 0 0 0 2 0 0 0 0 0 0 2 2 1 7 
206 Thangavel M 3 0 2 2 0 0 0 2 0 2 0 2 2 3 18 
207 Jeyaprakash M 2 2 2 2 0 0 0 0 0 0 0 2 2 2 14 
208 Ayyasamy M 3 1 2 0 0 0 0 0 0 0 0 2 1 1 10 
209 Senniyammal F 3 0 0 0 0 0 0 0 2 0 0 2 1 1 9 
210 Vaisali F 2 0 0 0 0 0 0 0 0 0 1 0 1 1 5 
211 Pratheep M 1 2 2 0 0 0 2 2 0 0 0 2 1 1 13 
212 Dhinesh M 1 1 2 0 0 0 0 0 0 0 1 0 0 1 6 
213 Dhinakar M 2 0 2 0 0 0 0 0 0 0 0 2 1 1 8 
214 Jeyabalan M 2 0 2 2 0 0 0 2 0 0 0 2 2 2 14 
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215 Manikam M 1 3 2 0 0 0 2 0 0 0 0 2 2 3 15 
216 Guruvan M 0 0 2 0 0 0 0 0 0 0 0 2 2 1 7 
217 Tamilan M 0 0 2 0 0 0 0 0 0 0 0 2 2 2 8 
218 Arunraj M 1 3 2 0 0 0 0 2 0 0 0 2 2 2 14 
219 Devikala F 2 1 0 0 0 0 0 0 0 0 0 2 2 1 8 
220 Valli F 1 0 0 0 0 0 0 0 0 0 1 0 0 1 3 
221 Sudhakar M 2 0 0 0 0 0 0 0 0 0 1 0 1 1 5 
222 Suryadevi F 1 0 0 0 0 0 0 0 0 0 0 2 1 1 5 
223 Velan M 1 1 1 0 0 0 0 0 0 0 1 0 1 1 6 
224 Sukumar M 2 0 0 0 0 0 0 0 0 0 1 0 1 1 5 
 
